{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-009321","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.580979+00:00","generated_at":"2026-05-15T18:09:42.602188+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biofrontera reports positive Phase 2b results for Ameluz PDT in moderate-to-severe acne; plans FDA meeting in Q3 2026","bullets":["Phase 2b study: 3-hour Ameluz incubation achieved 57.97% reduction in inflammatory lesions vs 36.51% for vehicle.","25% of Ameluz patients met mIGA co-primary endpoint (clear/almost clear) vs 21.4% with vehicle.","Safety profile consistent with prior PDT; most treatment-related AEs were mild-to-moderate burning and pruritus.","85.7% of 3-hour Ameluz patients would choose PDT again; 71.4% rated esthetic outcome good/very good.","Company to present data to FDA in Q3 2026 to discuss next steps for acne vulgaris indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-009321","json":"https://secwatch.observer/filing/0001493152-26-009321.json","markdown":"https://secwatch.observer/filing/0001493152-26-009321.md","text":"https://secwatch.observer/filing/0001493152-26-009321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226009321/0001493152-26-009321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226009321/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:09:42.602188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}